Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17992084 | 0.91 | ACAT2 (0.36) | HDAC8HDAC6MRGPRX4HIF1AACAT2 | |
| SCHEMBL17992088 | 0.90 | LMNA (0.33) | HDAC8HDAC6MRGPRX4HIF1A | |
| SCHEMBL17992112 | 0.90 | HDAC8 (0.32) | HDAC8HDAC6MRGPRX4HIF1APARP1 | |
| SCHEMBL17757867 | 0.90 | PPM1D (0.44) | KMT2APPM1DHDAC8HDAC6MRGPRX4 | |
| SCHEMBL17992107 | 0.89 | ACAT2 (0.34) | KMT2AACAT2TSHR | |
| SCHEMBL14398518 | 0.86 | KMT2A (0.41) | KMT2AACAT2TSHR | |
| SCHEMBL17757467 | 0.86 | KMT2A (0.41) | KMT2AACAT2TSHR | |
| SCHEMBL17757653 | 0.86 | KMT2A (0.41) | KMT2AACAT2TSHR | |
| SCHEMBL19523254 | 0.85 | TDO2 (0.39) | HDAC8HDAC6PARP1 | |
| SCHEMBL19934614 | 0.85 | HIF1A (0.44) | PPM1DHIF1APARP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802956-B2 | Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MUNCHEN-DEUTSCHES FORSCHUNGSZENTRUM FUR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2017-10-31 | — | — | US | disclosed |
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | HELMHOLTZ ZENTRUM MUNCHEN (DE) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222025-A1 | SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH | AIFM2, BAD, AIFM1 | KMT2A 4303/4885PPM1D 1502/4885HDAC8 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.